Immunotherapeutic perspective for bispecific antibodies

被引：116

作者：

van Spriel, AB

van Ojik, HH

van de Winkel, JGJ

机构：

[1] Univ Med Ctr Utrecht, Dept Immunol, Immunotherapy Lab, NL-3584 EA Utrecht, Netherlands

[2] Univ Med Ctr Utrecht, Medarex Europe, NL-3584 EA Utrecht, Netherlands

[3] Univ Med Ctr Utrecht, Dept Internal Med, NL-3584 EA Utrecht, Netherlands

来源：

IMMUNOLOGY TODAY | 2000年 / 21卷 / 08期

关键词：

D O I：

10.1016/S0167-5699(00)01659-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Biospecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy. Several BsAb induce effective cytotoxicity as well as 'vaccine effects' in vivo. Here, Annemiek van Spriel and colleagues discuss how these results have catalysed renewed efforts to translate BsAb concepts into effective therapies.

引用

页码：391 / 397

页数：7

共 55 条

[1] Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γl Fc or CH3 region [J].